Matej Mikulic
Research expert covering health, pharma & medtech
Amgen - Statistics & Facts
Today, Amgen is the world’s largest pure-play medical biotechnology company, generating 33.4 billion U.S. dollars of revenue in 2024, a massive five-billion dollar increase compared to the preceding year. At the same time, the company employs approximately 27 thousand people worldwide. Biotechnology company Amgen was originally founded as AMGen in 1980, standing for Applied Molecular Genetics. The company is headquartered in Thousand Oaks, California, but has establishments in many other countries around the world.
The U.S. market is essential
Amgen is among the larger biotech and pharma companies by market capitalization worldwide. However, biopharmaceuticals manufactured by Amgen currently are not among the top leading biotech drugs worldwide. Prolia, Enbrel, and Xgeva are the company’s flagship products, responsible for about 30 percent of Amgen’s total revenue. But with 13 drugs, each generating more than one billion U.S. dollars of revenue as of 2024, Amgen owns a well-balanced product portfolio. This is different from a regional point of view, since Amgen generates over 70 percent of its revenues on the domestic U.S. market.Research and development
As is common in the biopharmaceutical industry, Amgen spends a significant proportion of its income on research and development. In 2024, Amgen spent some 18 percent of its total revenues on R&D purposes. More than 47 percent of six billion U.S. dollars of R&D spending was for late-stage clinical programs, while the rest was for discovery research, early pipeline, and marketed products. Amgen's focus therapeutic areas are oncology and hematology, inflammatory diseases, bone diseases, and cardiovascular diseases.Matej Mikulic
,
Feb 21, 2025
Matej Mikulic
Research expert covering health, pharma & medtech
